Background
The EBV protein Latent Membrane Protein-1 (LMP1) is known to constitutively activate B cells. The LMP1 signaling pathway mimics that of CD40, a molecule involved in dendritic cell activation and maturation. Therefore we decided to evaluate the use of LMP1 as a vaccine adjuvant for both dendritic cell therapeutic vaccines and DNA-based vaccines for HIV.
Methods
To determine activity, LMP1 was analyzed using a luciferase report assay for NF-kB and IFN-β. To establish if LMP1 could activate human monocyte-derived dendritic cells (DC), LMP1 transfected DC were analyzed for activation/maturation markers and cytokines. DC migration was determined using a transwell-migration assay. LMP1 was also evaluated in a DNA vaccination/flu challenge mouse model. To determine the benefits of incorporating LMP1 into a DC therapeutic vaccine, LMP1 was tested in a tumor DC therapy mouse model.
Results
LMP1 activated high levels of NF-kB and IFN-β when evaluated using a luciferase reported assay. On primary DC, LMP1 induced DC activation, maturation, and proinflammatory cytokines. LMP1 induced 2-fold higher migration rates compared to the mature-DC control. As a DNA vaccine for flu, the addition of LMP1 provided superior TNF-α and IFN-γ responses. LMP1 vaccinated animals cleared virus more quickly and in the high-dose lethal flu challenge, LMP1 afforded more protection. Finally, LMP1 enhanced a DC therapeutic vaccine in a tumor model. Tumor progression was slowed compared to antigen-loaded DC alone and positive control mimicmatured DC.
Conclusion
These data suggest that LMP1 is an effective vaccine adjuvant. LMP1 can enhance the activation, maturation, and functional activity of DC. LMP1 can inducing a strong CD8+ T cell response in several mouse models, most notably the flu viral challenge model. LMP1 increased antigen-specific CD8+ T cells, improved survival to lethal flu high-dose challenge, and slowed tumor progression. These results suggest that LMP1 is a promising adjuvant for prophylactic vaccines for HIV.
